5441722026-04-012026-06-305441722026-04-012026-06-30in-capmkt:OtherExpenses1Member5441722026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15441722026-04-012026-06-30ItemsThatWillBeReclassifiedToProfitAndLoss15441722026-04-012026-06-30AuditorDomain1iso4217:INRiso4217:INRxbrli:shares544172INDGNNOTLISTEDINE065X01017Indegene LimitedMain BoardEquity2026-04-012027-03-312026-07-302026-07-10INRMillionsQuarterlyFirst quarterSingle segmentWhere financial results contain both consolidated financial results and standalone financial results of the parent, segment information is required to be presented only in the consolidated financial results. Accordingly segment information has been presented in the consolidated financial results2026-07-3017:30:002026-07-3018:15:00Declaration of unmodified opinionfalsefalseNo external loans and debt securities held by Company2026-04-012026-06-30UnauditedStandalone34070000003390000003746000000000221700000027000000114000000588000000294600000080000000008000000001780000002300000020100000005990000000000599000000800000060700000048100000022.492.48002.492.48Earnings per share is not annualised for quarter ended <br /> All amounts in INR million except per share data and where otherwise stated <br /> <br /> 1 The above Standalone Financial Results of the Indegene Limited the Company have been prepared in accordance with Indian Accounting Standards Ind AS 34 Interim Financial Reporting recognition and measurement principles of Indian Accounting Standards Ind AS prescribed under Section 133 of the Companies Act 2013 as amended read with the relevant rules issued there under and in terms of Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations 2015 the Regulations Due to rounding off the numbers presented throughout may not add up precisely to the totals Caret symbol in the financial information denote amounts less than INR 5 lakhs <br /> <br /> 2 The above Standalone Financial Results have been reviewed by the Audit Committee held on 28 July 2026 and approved by the Board of Directors at its meeting held on 30 July 2026 The figures for the quarter ended 31 March 2026 are the balancing figures between audited figures in respect of full financial year upto 31 March 2026 and published unaudited year to date figures upto 31 December 2025 being the end of the third quarter of the previous financial year which were subject to limited review <br /> <br /> 3 The Standalone Financial Results for the quarter ended 30 June 2026 are available on the National Stock Exchange of India Limited URL wwwnseindiacom the BSE Limited website URL wwwbseindiacom and on the Companys website URL wwwindegenecom investorrelations <br /> <br /> 4 During the year ended 31 March 2025 the Company had completed Initial Public Offer IPO of 40766550 equity shares of face value of INR 2 each at an issue price of INR452 per share Issue price of INR 422 per share including a share premium of INR 420 per share for employee quota towards fresh issue comprising fresh issue of 16833818 shares aggregating to INR 7600 and offer for sale of 23932732 shares by selling shareholders aggregating to INR 10818 The equity shares of the Company are listed in National Stock Exchange of India Limited NSE and BSE Limited BSE on 13 May 2024 The Company has received an amount of INR 7246 net of Company s share of IPO expenses of INR 354 retained in the Public Offer Account to the extent unpaid from the proceeds of the fresh issue Out of the Company s shares of IPO expenses INR 319 has been adjusted to securities premium <br /> <br /> The utilization of IPO proceeds of INR 7246 is summarized as below <br /> Repayment or prepayment of indebtedness of one of the material Subsidiary ILSL Holdings Inc The amount to be utilised as per the offer document is 3950 The amount utilized up to 30 June 2026 is 3950 The amount unutilized as of 30 June 2026 is nil <br /> <br /> Funding the capital expenditure requirements of the Company and one of the material subsidiary Indegene Inc The amount to be utilised as per the offer document is 644 The amount utilized up to 30 June 2026 is 644 The amount unutilized as of 30 June 2026 is nil <br /> <br /> Technology cybersecurity and cloud infrastructure related cost The amount to be utilised as per the offer document is 350 The amount utilized up to 30 June 2026 is 350 The amount unutilized as of 30 June 2026 is nil <br /> <br /> General corporate purposes and inorganic growth The amount to be utilised as per the offer document is 2302 The amount utilized up to 30 June 2026 is 2302 The amount unutilized as of 30 June 2026 is nil <br /> <br /> The total amount to be utilised as per the offer document is 7246 The total amount utilized up to 30 June 2026 is 7246 The total amount unutilized as of 30 June 2026 is nil <br /> <br /> 1 Pursuant to the Special Resolution passed at the Shareholders Meeting held on 12 August 2025 the Company has revised the objects as per offer document As per the revised objects an amount of INR 37 is adjusted from funding capital expenditure requirements towards repayment of indebtedness of ILSL Holdings Inc for the difference arising due to exchange rate fluctuation as on the date of offer document and as on the date of repayment Further an amount of INR 350 is reclassified from funding capital expenditure requirement towards utilization for services including cloud infrastructure and security services productivity tools cybersecurity and support services availed by the Company and Indegene Inc Further the Board of Directors of the Company has approved the transfer of unutilized IPO expense towards funding capital expenditure requirement by way of Board Resolution passed on 29 January 2026 The unutilized amount of INR 2 has been transferred to the net IPO proceeds thereby increasing it from INR 7244 to INR 7246 and earmarked for funding capital expenditure requirements at the Company s office premises <br /> <br /> 2 During the year ended 31 March 2025 the Company has repaid loan of USD 47 million and 200 thousands or INR 3950 outstanding in the books of ILSL Holdings Inc material subsidiary in line with Object 1 of the offer document The amount of INR 37 utilised over and above the maximum amount specified as per the original amount as per offer document of INR 3913 was due to exchange rate fluctuation as on the date of offer document and as on the date of payment The Special Resolution passed on 12 August 2025 revises the object amount to adjust this difference <br /> <br /> Out of the net proceeds there are no amounts that are unutilised as of 30 June 2026 <br /> <br /> 5 The Company publishes this Standalone Financial Results along with the Consolidated Financial Results In accordance with Ind AS 108 Operating Segments the Company has disclosed the segment information in the Consolidated Financial Results <br /> <br /> 6 The Board of Directors in its meeting on 29 April 2026 have proposed a final dividend of INR 2 and 25 paise per equity shares for the financial year ended 31 March 2026 The proposal is subject to the approval of shareholders at the ensuing Annual General Meeting and if approved would result in a cash outflow of approximately INR 542 <br /> Other Expenses588000000Remeasurement of defined benefit obligation-29000000-29000000-7000000Net change in fair value of forward contracts designated as cash flow hedges4000000040000000100000008000000UnauditedtrueDeloitte Haskins & Sellstrue2028-04-30